Activation mechanism of coronavirus membrane fusion protein | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Start & end year
2020
2023
Known Financial Commitments (USD)
$41,106
Funder
KAKENHI
Principal Investigator
Matsuyama Shutoku Unspecified
Research Location
Japan
Lead Research Institution
National Institute of Infectious Diseases
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

4 Publications linked via Europe PMC

Last Updated:6 days ago

View all publications at Europe PMC

Biochemical analysis of packing and assembling heptad repeat motifs in the coronavirus spike protein trimer.

Frequent occurrence of mutations in nsp3 and nsp4 of SARS-CoV-2, presumably caused by the inhaled asthma drug ciclesonide.

The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells.

The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells.